DAT is a major target of methylphenidate and amphetamine, and many treatments for ADHD, including the noradrenaline transporter inhibitor atomoxetine, are thought to increase cortical dopamine levels [74], consistent with a role for COMT. This evidence concerns the gene SLC6A3 and attention deficit-hyperactivity disorder.